首页> 外文期刊>Saudi Journal of Anaesthesia >The optimal effect-site concentration of sufentanil for laryngeal mask insertion during induction with target-controlled propofol infusion at 4.0 μg/mL
【24h】

The optimal effect-site concentration of sufentanil for laryngeal mask insertion during induction with target-controlled propofol infusion at 4.0 μg/mL

机译:靶控控异丙酚输注诱导时喉罩插入舒芬太尼的最佳作用部位浓度为4.0μg/ mL

获取原文
           

摘要

Objective: The objective of this study is to determine the optimal effect-site concentration (Ce) of sufentanil for satisfactory insertion of laryngeal mask airway (LMA) when administered with a target-controlled infusion (TCI) of propofol at 4.0 μg/mL. Materials and Methods: A total of 25 adult patients scheduled for minor elective surgery were enrolled in this study. All patients received induction with a combination of propofol and sufentanil TCI. The TCI of sufentanil was started at a target Ce of 0.1 ng/mL. After equilibrium with the plasma concentration, the TCI of propofol was initiated, targeting a preset Ce of 4.0 μg/mL. After the loss of consciousness, LMA was inserted and assessed by an experienced Anesthesiologist. The Ce of sufentanil for the next patient was guided by modified Dixon's up-and-down method using 0.05 ng/mL as a step size. The Ce of sufentanil required for successful LMA insertion in 50% of adults (EC50) was determined by calculating the midpoint concentration of all independent pairs of patients after at least seven crossover points. Results: The optimal Ce (EC50) of sufentanil for LMA insertion during propofol induction using target Ce of 4 μg/mL was 0.16 ng/mL (95% confidence interval [CI] = 0.12-0.20). There was a significant reduction in propofol induced pain score P = 0.0275 and insignificant hemodynamic changes. Conclusion: Ce of sufentanil required for successful LMA insertion in 50% of patients (EC50) using propofol target Ce of 4.0 μg/mL was 0.16 ng/mL (95% CI = 0.12-0.20) with a significant reduction in the propofol induced pain and hemodynamic stability.
机译:目的:本研究的目的是确定以4.0μg/ mL丙泊酚的靶控输注(TCI)给药时,舒芬太尼能令人满意地插入喉罩气道(LMA)的最佳作用部位浓度(Ce)。材料和方法:共有25名计划进行小型择期手术的成年患者参加了这项研究。所有患者均接受丙泊酚和舒芬太尼TCI联合诱导。舒芬太尼的TCI在目标Ce为0.1 ng / mL时开始。与血浆浓度达到平衡后,启动丙泊酚的TCI,目标预设Ce为4.0μg/ mL。失去知觉后,将LMA插入并由经验丰富的麻醉师进行评估。采用改良的Dixon上下法,以0.05 ng / mL作为步长,指导下一例患者的舒芬太尼Ce含量。成功地将LMA插入50%的成年人所需的舒芬太尼Ce(EC50)通过计算至少七个交叉点后所有独立对患者的中点浓度来确定。结果:使用4μg/ mL的目标Ce诱导异丙酚诱导LMA插入舒芬太尼的最佳Ce(EC50)为0.16 ng / mL(95%置信区间[CI] = 0.12-0.20)。异丙酚引起的疼痛评分P = 0.0275显着降低,并且血液动力学变化不明显。结论:使用异丙酚目标Ce为4.0μg/ mL的50%的患者成功成功插入LMA的舒芬太尼Ce(EC50)的Ce为0.16 ng / mL(95%CI = 0.12-0.20),并显着降低了由异丙酚引起的疼痛和血液动力学稳定性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号